Ingrid A Binswanger1,2,3, Stephen Koester4,5, Shane R Mueller6,7,5, Edward M Gardner8, Kristin Goddard6, Jason M Glanz6,9. 1. Institute for Health Research, Kaiser Permanente Colorado, P.O Box 378066, Denver, CO, 80237-8066, USA. Ingrid.A.B.inswanger@kp.org. 2. Division of General Internal Medicine, University of Colorado Denver School of Medicine, Aurora, CO, USA. Ingrid.A.B.inswanger@kp.org. 3. Denver Health and Hospital Authority, Denver, CO, USA. Ingrid.A.B.inswanger@kp.org. 4. Department of Anthropology, University of Colorado Denver, Denver, CO, USA. 5. Department of Health and Behavioral Sciences, University of Colorado Denver, Denver, CO, USA. 6. Institute for Health Research, Kaiser Permanente Colorado, P.O Box 378066, Denver, CO, 80237-8066, USA. 7. Division of General Internal Medicine, University of Colorado Denver School of Medicine, Aurora, CO, USA. 8. Denver Health and Hospital Authority, Denver, CO, USA. 9. Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.
Abstract
BACKGROUND: The rate of fatal unintentional pharmaceutical opioid poisonings has increased substantially since the late 1990s. Naloxone is an effective opioid antidote that can be prescribed to patients for bystander use in the event of an overdose. Primary care clinics represent settings in which large populations of patients prescribed opioids could be reached for overdose education and naloxone prescription. OBJECTIVE: Our aim was to investigate the knowledge, attitudes and beliefs about overdose education and naloxone prescription among clinical staff in primary care. DESIGN: This was a qualitative study using focus groups to elucidate both clinic-level and provider-level barriers and facilitators. SETTING: Ten primary care internal medicine, family medicine and infectious disease/HIV practices in three large Colorado health systems. METHODS: A focus group guide was developed based on behavioral theory. Focus group transcripts were coded for manifest and latent meaning, and analyzed for themes using a recursive approach that included inductive and deductive analysis. RESULTS: Themes emerged in four content areas related to overdose education and naloxone prescription: knowledge, barriers, benefits and facilitators. Clinical staff (N = 56) demonstrated substantial knowledge gaps about naloxone and its use in outpatient settings. They expressed uncertainty about who to prescribe naloxone to, and identified a range of logistical barriers to its use in practice. Staff also described fears about offending patients and concerns about increased risk behaviors in patients prescribed naloxone. When considering naloxone, some providers reflected critically and with discomfort on their own opioid prescribing. These barriers were balanced by beliefs that prescribing naloxone could prevent death and result in safer opioid use behaviors. LIMITATIONS: Findings from these qualitative focus groups may not be generalizable to other settings. CONCLUSION: In addition to evidence gaps, logistical and attitudinal barriers will need to be addressed to enhance uptake of overdose education and naloxone prescription for patients prescribed opioids for pain.
BACKGROUND: The rate of fatal unintentional pharmaceutical opioid poisonings has increased substantially since the late 1990s. Naloxone is an effective opioid antidote that can be prescribed to patients for bystander use in the event of an overdose. Primary care clinics represent settings in which large populations of patients prescribed opioids could be reached for overdose education and naloxone prescription. OBJECTIVE: Our aim was to investigate the knowledge, attitudes and beliefs about overdose education and naloxone prescription among clinical staff in primary care. DESIGN: This was a qualitative study using focus groups to elucidate both clinic-level and provider-level barriers and facilitators. SETTING: Ten primary care internal medicine, family medicine and infectious disease/HIV practices in three large Colorado health systems. METHODS: A focus group guide was developed based on behavioral theory. Focus group transcripts were coded for manifest and latent meaning, and analyzed for themes using a recursive approach that included inductive and deductive analysis. RESULTS: Themes emerged in four content areas related to overdose education and naloxone prescription: knowledge, barriers, benefits and facilitators. Clinical staff (N = 56) demonstrated substantial knowledge gaps about naloxone and its use in outpatient settings. They expressed uncertainty about who to prescribe naloxone to, and identified a range of logistical barriers to its use in practice. Staff also described fears about offending patients and concerns about increased risk behaviors in patients prescribed naloxone. When considering naloxone, some providers reflected critically and with discomfort on their own opioid prescribing. These barriers were balanced by beliefs that prescribing naloxone could prevent death and result in safer opioid use behaviors. LIMITATIONS: Findings from these qualitative focus groups may not be generalizable to other settings. CONCLUSION: In addition to evidence gaps, logistical and attitudinal barriers will need to be addressed to enhance uptake of overdose education and naloxone prescription for patients prescribed opioids for pain.
Entities:
Keywords:
HIV; naloxone; opioids; overdose; primary care; qualitative research
Authors: Michael J Silverberg; Gary Thomas Ray; Kathleen Saunders; Carolyn M Rutter; Cynthia I Campbell; Joseph O Merrill; Mark D Sullivan; Caleb J Banta-Green; Michael Von Korff; Constance Weisner Journal: Clin J Pain Date: 2012-01 Impact factor: 3.442
Authors: Cunlin Wang; David Vlahov; Noya Galai; Stephen R Cole; Joseph Bareta; Robin Pollini; Shruti H Mehta; Kenrad E Nelson; Sandro Galea Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: Jane A Gwira Baumblatt; Caleb Wiedeman; John R Dunn; William Schaffner; Leonard J Paulozzi; Timothy F Jones Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Julia L Marcus; David V Glidden; Kenneth H Mayer; Albert Y Liu; Susan P Buchbinder; K Rivet Amico; Vanessa McMahan; Esper Georges Kallas; Orlando Montoya-Herrera; Jose Pilotto; Robert M Grant Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff Journal: BMJ Date: 2013-01-30
Authors: Jo Ann Shoup; Shane R Mueller; Ingrid A Binswanger; Anna V Williams; John Strang; Jason M Glanz Journal: Pain Med Date: 2020-10-01 Impact factor: 3.750
Authors: Ronald P Jordan; Jeffrey Bratberg; Heather B Congdon; L Brian Cross; Lucas G Hill; Joel C Marrs; Sarah McBane; William G Lang; Jeffrey O Ekoma Journal: Am J Pharm Educ Date: 2017-10 Impact factor: 2.047
Authors: Shane R Mueller; Stephen Koester; Jason M Glanz; Edward M Gardner; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2016-10-31 Impact factor: 5.128
Authors: Traci C Green; Corey Davis; Ziming Xuan; Alexander Y Walley; Jeffrey Bratberg Journal: Am J Public Health Date: 2020-04-16 Impact factor: 9.308